Post hoc analysis of the LAMP RCT (510 of 636 patients with minor ischaemic stroke or high-risk TIA and type 2 diabetes): in those with HOMA-IR ≥2.5, 3-month stroke recurrence was 5.8% with liraglutide vs 18.1% without; no significant benefit below 2.5.
Secondary analysisn = 510
Lu et al. Liraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP Trial